Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2004-10-25
2011-10-18
Marvich, Maria (Department: 1633)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C514S001000, C530S388210
Reexamination Certificate
active
08039587
ABSTRACT:
Methods and compositions for delivering polynucleotides are provided. One embodiment provides a non-viral vector comprising a recombinant polynucleotide-binding protein comprising a protein transduction domain operably linked to a targeting signal. Methods for modifying the genome of non-nuclear organelles are also provided.
REFERENCES:
patent: 5804445 (1998-09-01), Brasier
patent: 5831020 (1998-11-01), Citovsky
patent: 6017734 (2000-01-01), Summers
patent: 6127159 (2000-10-01), Fuller et al.
patent: 6506559 (2003-01-01), Fire et al.
patent: 6531647 (2003-03-01), Baulcombe et al.
patent: 6759574 (2004-07-01), Ream, Jr. et al.
patent: 6835810 (2004-12-01), Hwu
patent: 6903077 (2005-06-01), Heintz
patent: 7001768 (2006-02-01), Wolffe
patent: 2002/0086356 (2002-07-01), Tuschl et al.
patent: 2002/0132990 (2002-09-01), Huston
patent: 2002/0155095 (2002-10-01), Nagabhushan
patent: 2003/0104622 (2003-06-01), Robbins et al.
patent: 2003/0186233 (2003-10-01), Chesnut et al.
patent: 2003/0237112 (2003-12-01), Brown et al.
patent: 2004/0072739 (2004-04-01), Anderson et al.
patent: 2004/0091878 (2004-05-01), Sera
patent: 2004/0176282 (2004-09-01), Dalby et al.
patent: 2005/0015830 (2005-01-01), Dorokhov et al.
patent: 2005/0042603 (2005-02-01), Wang
patent: 2005/0147993 (2005-07-01), Khan
patent: 2006/0211647 (2006-09-01), Khan
patent: 2007/0196334 (2007-08-01), Khan
patent: 2008/0222750 (2008-09-01), Khan
patent: 2009/0123468 (2009-05-01), Khan
patent: 2009/0208478 (2009-08-01), Khan
patent: 2009/0227655 (2009-09-01), Khan
patent: 198 56 052 (2000-06-01), None
patent: 20030012226 (2003-02-01), None
patent: WO 97/27742 (1997-08-01), None
patent: WO 98/46271 (1998-10-01), None
patent: WO 9856938 (1998-12-01), None
patent: WO 00/19993 (2000-04-01), None
patent: WO 00/12732 (2000-09-01), None
patent: WO 00/58488 (2000-10-01), None
patent: WO 01/75164 (2001-10-01), None
patent: WO 03/025195 (2003-03-01), None
patent: WO 03/052067 (2003-06-01), None
patent: WO 03/076561 (2003-09-01), None
patent: WO 2004/061456 (2004-07-01), None
Fortunati et al, A multi-domain protein for b1 integrin-targeted DNA delivery, Gene Therapy (2000) 7, 1505-1515.
Krueger et al, Peripheral-type benzodiazepine receptors mediate translocation of cholesterol from outer to inner mitochondrial membranes in adrenocortical cells, J. Biol. Chem., vol. 265, Issue 25, 15015-15022, Sep. 1990.
Futaki et al, Arginine-rich Peptides, The Journal of Biological Chemistry vol. 276, No. 8, Issue of Feb. 23, pp. 5836-5840, 2001.
Noguchi et al, Protein transduction technology offers a novel therapeutic approach for diabetes, J Hepatobiliary Pancreat Surg (2006) 13:306-313.
Jacobs et al, Making mitochondrial mutants, TRENDS in Genetics vol. 17 No. 11 Nov. 2001.
Sandig V, Stamm W, Behlke J, Bottger M, Strauss M (1995) Direct gene transfer of HMG1 based DNA-protein complexes (abstract). J Mol Med 73: B10.
Brydges et al, Mutation of an unusual mitochondrial targeting sequence of SODB2 produces multiple targeting fates inToxoplasma gondii, Journal of Cell Science, 2003, 116 (22), 4675-4685.
Gaizo et al., (2003) “A Novel TAT-Mitochondrial Signal Sequence Fusion Protein Is Processed, Stays in Mitochondria, and Crosses the Placenta”Molecular Therapyvol. 7, No. 6, pp. 720-730.
Gaizo et al., (2003) “Targeting proteins to mitochondria using TAT”,Molecular Genetics and Metabolism 80pp. 170-180.
U.S. Appl. No. 10/561,829, filed Dec. 21, 2005, Khan.
Alam, et al., “Human mitochondrial DNA is packaged with TFAM”,Nucleic Acids Res., 31(6):1640-5 (2003).
Cline and Henry “Import and routing of nucleus-encoded chloroplast proteins”,Annu. Rev. Cell Dev. Biol., 12:1-26 (1996).
Derossi, et al., “The third helix of the Antennepedia homeodomain translocates through biological membranes”,J. Biol. Chem., 269(14):10444-50 (1994).
Emanuelsson, et al., “Predicting subcellular localization of proteins based on their N-terminal amino acid sequence”,J. Mol. Biol., 300(4):1005-16 (2000).
Frankel and Pabo, “Cellular uptake of the tat protein from human immunodeficiency virus”,Cell, 55(6):1189-93 (1988).
Ho, et al., “Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo”,Cancer Res., 61(2):474-7 (2001).
Kabouridis, “Biological applications of protein transduction technology”,Trends Biotechnol., 21(11):498-503 (2003).
Murphy, “Selective targeting of bioactive compounds to mitochondria”,Trends Biotechnol., 15(8):326-30 (1997).
Sandman, et al., “Diversity of prokaryotic chromosomal proteins and the origin of the nucleosome”,Cell. Mol. Life Sci., 54(12):1350-64 (1998).
Weissig, “Mitochondrial pharmaceutics”,Mitochondrion, 3(4):229-44 (2004).
Wender, et al., “The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters”,Proc. Natl. Acad. Sci. U.S.A., 97(24):13003-8 (2000).
Chinnery, et al., “Peptide nucleic acid delivery to human mitochondria”,Gene Ther., 6(12):1919-28 (1999).
Flierl, et al., “Targeted delivery of DNA to the mitochondrial compartment via import sequence-conjugated peptide nucleic acid”,Mol. Ther., 7(4):550-7 (2003).
Muratovska, et al., “Targeting peptide nucleic acid (PNA) oligomers to mitochondria within cells by conjugation to lipophilic cations: implications for mitochondrial DNA replication, expression and disease”,Nucleic Acids Res., 29(9):1852-63 (2001).
Ross, et al., “Cell-penetrating peptides do not cross mitochondrial membranes even when conjugated to a lipophilic cation: evidence against direct passage through phospholipid bilayers”,Biochem. J., 383(Pt. 3):457-68 (2004).
Smith, et al., “Delivery of bioactive molecules to mitochondria in vivo”,Proc. Natl. Acad. Sci. U.S.A., 100(9):5407-12 (2003).
Bayona-Bafaluy, “Rapid directional shift of mitochondrial DNA heteroplasmy in animal tissues by a mitochondrially targeted restriction endonuclease,”Proc. Natl. Acad. Sci. U S A. 102(40):14392-7(2005).
D'Souza “Gene therapy of the other genome: the challenges of treating mitochondrial DNA defects”Pharm Res.24(2):228-38(2007).
Del Gaizo, “A novel TAT-mitochondrial signal sequence fusion protein is processed, stays in mitochondria, and crosses the placenta,”Mol. Ther.7(6):720-30(2003).
Flierl, “Targeted delivery of DNA to the mitochondrial compartment via import sequence-conjugated peptide nucleic acid,”Mol. Ther.7(4):550-7(2003).
Khan, “Development of mitochondrial gene replacement therapy,”J. Bioenergetics and Biomembranes36L387-393(2004).
Maliga, “Plant Biotechnology 2007: all three genomes make contributions to progress”Current Opinion in Biotech.18:97-99(2007).
Murphy, “Selective Targeting of Bioactive Compounds to Mitochondria,”Trends in Biotech.15(8):326-30(1997).
Seibel, “Transfection of mitochondria: strategy towards a gene therapy of mitochondrial DNA diseases,”Nucleic Acids Res.23(1):10-17(1995).
Shore, “Import and insertion of proteins into the mitochondrial outer membrane”Eur. J. Biochem.227:9-18(1995).
Sloots, “Recombinant derivatives of the human high-mobility group protein HMGB2 mediate efficient nonviral gene delivery”FEBS272:4221-4236(2005).
Srivastava, “Manipulating mitochondrial DNA heteroplasmy by a mitochondrially targeted restriction endonuclease,”Hum. Mol. Genet.10(26):3093-9(2001).
Tanaka, “Gene therapy for mitochondrial disease by delivering restriction endonuclease Smal into mitochondria,”J. Biomed. Sci. 9(6 Pt 1):534-41(2002).
Vestweber, “DNA-protein conjugates can enter mitochondria via the protein import pathway,”Nature338(6211):170-2(1989).
Opalanska, et al., “Nucleic-acid therapeutics: basic principles and recent applications”,Nat. Rev. Drug. Dis., 1:503-514 (2002).
Russell, “Replicati
Gencia Corporation
Marvich Maria
Pabst Patent Group LLP
LandOfFree
Methods and compositions for delivering polynucleotides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for delivering polynucleotides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for delivering polynucleotides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4281756